On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies.
Unkel S, Amiri M, Benda N, Beyersmann J, Knoerzer D, Kupas K, Langer F, Leverkus F, Loos A, Ose C, Proctor T, Schmoor C, Schwenke C, Skipka G, Unnebrink K, Voss F, Friede T.
Unkel S, et al.
Pharm Stat. 2019 Mar;18(2):166-183. doi: 10.1002/pst.1915. Epub 2018 Nov 20.
Pharm Stat. 2019.
PMID: 30458579
Free PMC article.